Abstract
Less than 3% of people who get infected with COVID-19 need hospital treatment. However, up to one-third of the hospitalized patients with COVID-19 require invasive mechanical ventilation. Ventilator-associated pneumonia (VAP), caused by the multidrug-resistant Acinetobacter baumannii (A. baumannii), is an emerging infection in the intensive care units and can have fatal consequences for those patients who already have critical COVID-19. Countries of the Balkan peninsula have an exceptionally high prevalence of invasive carbapenem-resistant Acinetobacter spp in the hospital setting. Diagnosing this type of pneumonia is a challenging process. Furthermore, treatment complexities arise because of multidrug resistance. Novel therapeutic agents, such as sulbactam/durlobactam and zosurabalpin could be the new therapeutic opportunity for A. baumannii-induced VAP. Antimicrobial resistance of A. baumannii is not entirely understood, although several mechanisms have been identified. To adequately manage VAP it is important to isolate causative agents, have awareness of the resistance pattern, carefully dispense antibiotics, and identify risk factors. In this review, we discuss epidemiological characteristics, pathophysiological mechanisms, clinical presentation and diagnosis, as well as the current and novel treatments of A. baumannii-induced VAP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
